key: cord-0862984-94p10hil authors: Sobreira, Marcone Lima; Ramacciotti, Eduardo; Paschôa, Adilson Ferraz; Matielo, Marcelo Fernando; Casella, Ivan Benaduce; Yazbek, Guilherme; Soares, Raphael de Athayde; van Bellen, Bonno; Marques, Marcos Arêas title: Covid-19 vaccines and thromboembolic complications date: 2021-12-01 journal: Jornal Vascular Brasileiro DOI: 10.1590/1677-5449.210167 sha: 4e715565bac9227f4f4cc611a17f8e119a73662c doc_id: 862984 cord_uid: 94p10hil nan The study was carried out at Sociedade Brasileira de Angiologia e Cirurgia Vascular (SBACV), São Paulo, SP, Brazil. The current global pandemic caused by the novel coronavirus disease , which began in the city of Wuhan, in China, caused by a strain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infected around 18.77 million Brazilians, with approximately 525,500 deaths, according to data from the Ministry of Health, by July 2021. With regard to its wide clinical spectrum, which varies from an asymptomatic form to severe acute respiratory syndrome (SARS) , what has attracted the attention of angiologists and vascular surgeons are symptoms related to inflammation of the vascular system and hypercoagulability, leading to manifestations such as small vessel vasculitis and micro and macrovascular thrombosis of arteries and/or veins. 1 A recent metaanalysis of 102 studies involving 64,503 patients infected by the SARS-CoV-2 virus reported that the frequency of venous thromboembolism (VTE) related to Covid-19 was 14.7% (95% confidence interval [95%CI]: 12.1% to 17.6%) and the frequency of arterial thromboembolism (ATE) was 4.0% (95%CI: 2.0% to 6.5%). 2 The Covid-19 vaccines licensed for emergency use in Brazil in January 2021 demonstrated satisfactory safety and efficacy in clinical trials, and, despite the rapidity with which they were developed, all of them obligatorily followed rigid protocols and their data were evaluated by independent specialists and by Brazil's National Agency for Sanitary Vigilance (Agência Nacional de Vigilância Sanitária -ANVISA). Vaccination eliminates or drastically reduces the risk of sickness or of severe forms of the disease. The Covid-19 vaccines used in Brazil have the following efficacy rates: AstraZeneca®. The rate of notification of cases of VTE and ATE over that period for the total number of people vaccinated was 0.21 (95%CI: 0.19% to 0.22%) cases of thrombotic events per 1 million people vaccinated/day. For VTE and ATE, the rates were, respectively, 0.075 (95%CI: 0.07% to 0.08%) and 0.13 (95%CI: 0.12% to 0.14%) cases per 1 million people vaccinated/day. In Brazil, the rate was 0.89 events for each 100,000 doses administered, which is lower than the expected rate for the general population. As such, the risk-benefit profile of the vaccine is still favorable for these events. 4 Rare cases of thrombocytopenia were also reported and, despite the favorable risk-benefit profile, some European countries decided to no longer recommend the AstraZeneca® vaccine for women younger than 55 or 60 years. 4 The plausible explanation for the combination of VTE in atypical venous sites (cerebral and splanchnic veins) with thrombocytopenia is that an immune response is being triggered against platelet factor 4, leading to a major increase in activation and consumption of platelets, similar to heparin-induced thrombocytopenia in people who have not previously been exposed to heparins. D-dimer levels tend to be greatly elevated, but with normal fibrinogen levels. 5, 6 These thromboses occur around 4 to 24 days after administration of the vaccine 5 and predominantly in women aged 20 to 50 years of age. 5, 6 Clinical status tends to be severe and there are reports of mortality exceeding 50%. 5, 6 Both the WHO and the European Medicines Agency published favorable opinions, stating that these events are extremely rare and that the benefits of the AstraZeneca® vaccine (reducing morbidity and mortality related to Covid-19) greatly outweigh its potential risks, reiterating the importance of vaccination. Moreover, administration of the vaccine was resumed in the European countries that had suspended it. It should be pointed out that thromboembolic events occur naturally and frequently in the general population, regardless of vaccination. In general, the number of serious thrombotic events associated with the AstraZeneca® vaccine varied from 5.5 to 7.6 per million people vaccinated, illustrating the rarity of these events. 7, 8 Mathematical models estimate that the risk of thrombosis associated with this vaccine decreases as age increases, falling from an initial baseline of 1.9 per 100 thousand vaccinated people aged 20 to 29 years to 0.4 per 100 thousand vaccinated people over the age of 80. 9 Up to April of 2021, 7.98 million doses of the Janssen® vaccine had been administered, with just 15 confirmed cases of TTS, 7 with greatest incidence among female patients in the under-50 age group. To date, the Food and Drug Administration recommends continuing to administer the Janssen® vaccine to all age groups, irrespective of sex, with the observation that its information leaflet should mention the risk of TTS in female patients less than 50 years old. 10 Although there are few reports of adverse events related to the Sputnik V® vaccine, which is not yet being used in Brazil, it employs similar technology to the AstraZeneca® and Janssen® vaccines, which are both associated with TTS, which increases the likelihood that it would have the same side effects. 11 However, in a phase 3 trial with 21,977 randomized adults, just one patient developed VTE, probably related to a preexisting comorbidity. 12 There were no reports of VTE or ATE in a real-life study of Sputnik V®. 13 Finally, TTS should be suspected in patients with thromboembolic events associated with thrombocytopenia (<150,000/mm 3 Em que pese seu amplo espectro clínico, que varia desde a forma assintomática até a síndrome respiratória aguda grave (SARS), os sintomas relacionados à inflamação do sistema vascular e à hipercoagulabilidade que levam a manifestações como vasculite de pequenos vasos e trombose micro e macrovascular de artérias e/ou veias têm chamado atenção dos angiologistas e cirurgiões vasculares 1 . Em uma metanálise recente com 102 estudos envolvendo 64.503 pacientes infectados pelo vírus SARS-CoV-2, a frequência de tromboembolismo venoso (TEV) relacionado à covid-19 foi de 14,7% (intervalo de confiança de 95% [IC95%]: 12,1% a 17,6%) e a de tromboembolismo arterial (TEA) foi de 4,0% (IC95%: 2,0% a 6,5%) 2 . As vacinas para covid-19 licenciadas para uso emergencial no Brasil em janeiro de 2021 demonstraram ter segurança e eficácia satisfatórias em estudos clínicos, e, apesar da rapidez nos seus desenvolvimentos, todas passaram obrigatoriamente por rígidos protocolos e tiveram seus dados avaliados por especialistas independentes e pela Agência Nacional de Vigilância Sanitária (Anvisa). A vacinação elimina ou reduz drasticamente o risco de adoecimento ou das formas graves da doença. As vacinas contra a covid-19 utilizadas no Brasil apresentam as seguintes taxas de eficácia: Eventos tromboembólicos arteriais e venosos Smadja Raros casos de plaquetopenia também foram relatados, e, apesar do perfil de risco-benefício favorável, alguns países da Europa passaram a não recomendar a vacina AstraZeneca® para mulheres abaixo de 55 ou 60 anos 4 . A explicação plausível para a combinação de TEV em sítios venosos atípicos (veias cerebrais e esplâncnicas) e trombocitopenia seria o desencadeamento de uma resposta imunológica contra o fator 4 plaquetário, que levaria a um grande aumento na ativação e no consumo plaquetários, de forma semelhante à trombocitopenia induzida por heparina, em indivíduos não expostos previamente às heparinas. Os níveis de dímero-D costumam estar muito aumentados, porém com níveis de fibrinogênio normal 5,6 . Essas tromboses ocorreram cerca de 4 a 24 dias após a administração da vacina 5 e de forma predominante no sexo feminino, entre 20 e 50 anos de idade 5, 6 . O quadro clínico costuma ser grave, e há relatos de mortalidade superior a 50% 5,6 . Tanto a OMS quanto a Agência Europeia de Medicamentos emitiram parecer favorável, informando que os eventos são extremamente raros e que os benefícios da vacina AstraZeneca®, reduzindo a morbimortalidade relacionada à covid-19, superam em muito os seus potenciais riscos, o que reitera a importância da vacinação. Ademais, seu uso foi retomado nos países europeus. É necessário esclarecer que eventos tromboembólicos ocorrem natural e frequentemente na população geral, independentemente de vacinação. Em geral, o número de eventos trombóticos graves associados à vacina AstraZeneca® variou entre 5,5 a 7,6 por milhão de pessoas vacinadas, caracterizando a raridade do evento 7, 8 . Modelos matemáticos estimaram que o risco de trombose associado a essa vacina decresceu com o aumento da faixa etária, sendo inicialmente de 1,9 para 100 mil vacinados entre 20 e 29 anos e caindo para 0,4 para 100 mil vacinados acima dos 80 anos 9 . Até abril de 2021, 7,98 milhões de doses da vacina da Janssen® foram aplicadas, com apenas 15 casos confirmados de STT 7 , sendo a maior incidência em pacientes do sexo feminino, com faixa etária menor que 50 anos. A Food and Drug Administration, até o momento, recomenda a manutenção da vacina da Janssen® em todas as faixas etárias, independentemente do sexo, com a observação de que deva constar, na bula, o risco de STT em pacientes do sexo feminino com menos de 50 anos de idade 10 . Apesar de poucos relatos de eventos adversos relacionado à vacina Sputnik V®, ainda não utilizada no Brasil, ela apresenta uma tecnologia semelhante às vacinas AstraZeneca® e Janssen®, ambas associadas a STT, o que aumenta a possibilidade de ter os mesmos efeitos colaterais 11 . Porém, em estudo de fase 3, entre 21.977 adultos randomizados, apenas um paciente desenvolveu TEV, provavelmente relacionado a comorbidade preexistente 12 . Não houve relatos de TEV ou TEA em estudo de vida real com a Sputnik V® 13 . Por fim, deve-se suspeitar de STT em pacientes com eventos tromboembólicos associado a plaquetopenia (<150.000/mm 3 ) dentro de 28 dias após a vacinação. No manejo clínico, deve-se evitar o uso de qualquer heparina, dando-se preferência aos anticoagulantes de ação direta de uso oral ou fondaparinux. Nos casos mais graves, pode-se utilizar imunoglobulina humana endovenosa. O uso de corticosteroides também deve ser aventado em caso de atraso no uso da imunoglobulina humana 10 . A panaceia dos anticoagulantes na infecção pela COVID-19 Arterial and venous thromboembolism in COVID-19: a study-level metanalysis Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase Nota técnica nº 441/2021-CGPNI/ DEIDT/SVS/MS Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination A panaceia dos anticoagulantes na infecção pela COVID-19 Arterial and venous thromboembolism in COVID-19: a study-level metanalysis Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase Nota técnica nº 441/2021-CGPNI/ DEIDT/SVS/MS Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination SARS-CoV-2 vaccine and thrombosis: an expert consensus on vaccine-induced immune thrombotic thrombocytopenia Sputnik V vaccine goes global Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Active monitoring of early safety of Sputnik V vaccine in Buenos Aires Correspondência Marcos Arêas Marques Rua Assunção 217/704 -Bairro Botafogo CEP 22251-030 -Rio de Janeiro (RJ) mareasmarques@gmail.com Informações sobre os autores MLS -Livre-docente